

**File S1**  
**Supporting Materials and Methods**

**Preparation of human samples.** Whole blood samples from adults and cord blood were obtained from New York Blood Center (Long Island City, NY) and National Disease Research Interchange (Philadelphia, PA), respectively. To isolate mononuclear cells from whole blood, samples were mixed with 1-2 times their volume of PBS-EDTA. This diluted blood was layered over Ficoll-paque Plus (GE Healthcare), then centrifuged at 400g for 30 minutes at room temperature. Mononuclear cells at the interface between plasma and Ficoll were collected and washed with PBS-EDTA. To isolate CD8<sup>+</sup> T cells from this fraction, a Naive CD8<sup>+</sup> T Cell Isolation Kit (human) (Miltenyi) was used according to manufacturers' instructions. Following isolation, cells were placed in Trizol (Life Technologies).

**Mice.** gBT-I TCR transgenic mice (TCR $\alpha\beta$  specific for SSIEFARL peptide from HSV-1 glycoprotein B498-505) were provided by Dr. Janko Nikolich-Zugich (University of Arizona, Tucson, AZ). Ly5.2 mice (8-12 wk) were purchase from The National Cancer Institute (Fredrick, MD). Rag-/- OT-I mice were purchased from Taconic (Germantown, NY) and were crossed to C57Bl/6 mice from The National Cancer Institute and F1 progeny were used.

**Antibodies, Staining and Flow Cytometry.** The fluorochrome labeled monoclonal antibodies anti-CD8 $\alpha$  (53-6.7), anti-CD4 (GK1.5), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD90.1/Thy1.1 (OX-7), anti-KLRG1 (2F1), anti-CD127 (A7R34), anti-CD62L (MEL-14), anti-CD44 (clone), anti-Eomes (Dan11mag), anti-T-bet (eBio4B10), anti-CXCR3 (CXCR3-173), anti-CCR5 (HM-CCR5), anti-CCR7 (4B12) and anti-gp130 (KGP130) were purchased from Biolegend (San Diego, CA), eBioscience (San Diego, CA), Life technologies (Carlsbad, CA) or BD Biosciences (San Jose, CA).

**Sorting.** Splenocytes were harvested and positive magnetic selection was performed using anti-CD8 beads (Miltenyi Biotec, Auburn, CA), according to manufacturer's instructions. Following purification, cells were labeled with anti-CD4-fluorescein isothiocyanate, anti-CD8-e450, anti-Thy1.1-allophycocyanin, anti-CD45.2,-allophycocyanin-e780 and anti-CD45.1-phycoerythrin-Cy7 for 30 min at 4°C. Labeled cells were washed twice and placed in sorting buffer (PBS, 0.5% BSA, 2 mM EDTA). We concurrently sorted for CD8<sup>+</sup>CD4<sup>+</sup>CD45.1<sup>-</sup>CD45.2<sup>+</sup>Thy1.1<sup>+</sup> and CD8<sup>+</sup>CD4<sup>+</sup>CD45.1<sup>-</sup>CD45.2<sup>+</sup>Thy1.1<sup>-</sup> populations and achieved >95% purity. Sorting was performed on a FACS Aria (BD Biosciences).

**RNA isolation.** Cells were resuspended in Trizol (Life Technologies) at a concentration of 1 million cells/mL and stored at -80°C. RNA isolation was completed within a month. To do so, the samples were thawed and 200  $\mu$ L of chloroform per mL Trizol was added. The tubes were shook for 15 seconds, then incubated at room temperature for ten minutes to allow for phase separation. The tubes were centrifuged for 15 minutes at 12,000xg at 4°C. The upper aqueous phase was transferred to a fresh

tube, and 1  $\mu$ L glycobule (Life Technologies) was added to help visualize the RNA pellet. To precipitate the RNA, we added 0.5 mL isopropanol per mL Trizol, then incubated at room temperature for ten minutes, then centrifuged for ten minutes at 12,000xg at 4°C. The supernatant was pipetted off, and the pellet was washed in 1 mL 75% ethanol, then centrifuged for ten minutes at 12,000xg at 4°C. The supernatant was pipetted off and the RNA pellet was allowed to air dry for ten minutes. The RNA was then resuspended in 20  $\mu$ L RNase-free water (HyClone).

**Small RNA-Seq analysis.** We used miRDeep2 to align and quantify sequencing reads to known mouse miRNAs (Friedländer *et al.* 2012). For aligning, we inputted the raw sequencing files into the script mapper.pl (a component of miRDeep2) which trimmed the adapter sequence (TGGAATTCTCGGGTGCCAAGG for libraries generated with Illumina, AGATCGGAAGAGCACACGTCT for libraries generated with NEB), discarded reads with fewer than 18 nucleotides, aligned the reads to the genome (mm9) using Bowtie (Langmead *et al.* 2009). We used options `-e`, `-h`, `-i`, `-j`, `-k`, `-l 18`, and `-m`.

Genome-matching reads were matched to known mouse miRNAs from miRBase version 21 (Kozomara and Griffiths-Jones 2014) and quantified using the script quantifier.pl (a component of miRDeep2) using options `-d` and `-t mmu`. The defaults we used allow one mismatch and allow 2 nucleotides upstream and 5 nucleotides downstream of the mature sequence.

For each miRNA, we normalized the number of reads in each sample by the total number of miRNA-matching reads, then found all miRNAs with >1000 RPM (well-expressed) in at least one sample. We then combined those miRNAs that come from the same miRNA family, as defined by having the same composition at nucleotides 2-8. We used the raw read counts for those miRNA families when finding fold-change differences and differential expression using edgeR (Robinson *et al.* 2010). When using edgeR, we calculated normalization factors, estimated common and tagwise dispersion, and performed exact tests on each adult and neonatal pair for naïve, 5-dpi, and 7-dpi samples. The p-values are multiple test corrected using the Benjamini-Hochberg method.

Clustering was performed using the Euclidean method in the R package gplots. Principal component analysis was performed on  $\log_{10}$ (RPM) values for the miRNAs with >1000 RPM in at least one sample.

**mRNA-Seq analysis.** We trimmed nucleotides from the ends of sequencing reads if they had Phred quality scores <20. Reads that were at least 20 nucleotides long after trimming were aligned to the genome (mm9) using Tophat (Trapnell *et al.* 2009) with the option `--no-novel-juncs`. We used the mm9 GTF file provided by UCSC (available from the Tophat website). Differential expression of genes between samples was determined using CuffDiff (Trapnell *et al.* 2013) with a false discovery rate of 5%.

**Clustering gene expression data.** We clustered expressed genes that were significantly differentially expressed, and had at least a 2-fold difference in expression between adults and neonates in at least one sample (naïve, 5-dpi, 7-dpi, or 15-dpi). Those genes were grouped into five clusters using the partitioning around medoids method (Reynolds *et al.* 2006) in R.

**Enrichment statistics.** Gene sets were downloaded from the Immunologic Signatures collection at the Molecular Signatures Database (MSDB). We found the number of genes from each dataset that belonged to a cluster. For each cluster, we found the number of genes that were found in both the cluster and the dataset ( $b$ ), the total number of genes present in that cluster ( $n$ ), the number of genes in the MSDB dataset ( $B$ ), and the total number of genes that had been clustered ( $N$ ). Enrichment was calculated as  $\frac{b/n}{B/N}$ . One-sided Fisher exact tests were used to measure significance.

**3'-Seq.** 3'-Seq was performed as described in (Lianoglou *et al.* 2013) (full protocol available at <http://www.mskcc.org/sites/www.mskcc.org/files/node/25002/documents/3%27-seq%20protocol.pdf>). Briefly, 1 ug of DNase-treated (Ambion) total RNA was incubated with a biotinylated polyT primer that contained a single RNA base (IDT) and Dynabeads M280 Steptavidin (Life Technologies). The RNA attached to the beads underwent first strand synthesis with SuperScriptIII (Life Technologies), then second strand synthesis with DNA Pol I (NEB) and RNaseH (NEB). The cDNA was nicked using RNase HII to introduce then translated with DNA Pol I (NEB) for 8 minutes at 8°C. After stopping the reaction with EDTA at 50 mM, the ends were cleaned up with T7 exonuclease (NEB), mung bean exonuclease (NEB), and Klenow enzyme (NEB) supplemented with dNTPs. Adapters were ligated with T4 DNA ligase (NEB), then amplified with Phusion (Fermentas). After the libraries were purified by PAGE, they were sequenced on the Hi-Seq platform with 100 bp reads.

**3'-Seq analysis.** To ensure that we were examining reads that captured the ends of 3'UTRs, we required that 3'-Seq reads contain the 3' adapter sequence adjacent to a stretch of A's. We then trimmed the A's and the adapter sequence from the 3' end of the read, then trimmed low quality nucleotides (Phred <20) from the 5' and 3' end of the read. Trimmed reads that were at least 20 nucleotides long, and were not derived from rRNA (removed using local alignment Bowtie2) (Langmead *et al.* 2009; Langmead and Salzberg 2012)

<sup>9</sup>, were then mapped to the mouse genome (mm9) using Tophat. The 3' end of uniquely matching reads were mapped and counted using the Genomcov tool from Bedtools (Quinlan and Hall 2010). We kept reads that mapped either in an annotated mouse 3'UTR (RefSeq, mm9) or within 1500 nt downstream, and we only considered the longest annotated 3'UTR isoform for genes that are reported to have multiple isoforms. We then determined which reads were within 50 nucleotides of a putative polyadenylation sequence (PAS, AATAAA or ATTA AAA), and used those in further analyses.

For each gene, an isoform was considered if it contained at least 20% of the reads for that gene. For genes that were targets of miR-29a-3p or miR-130b-3p and that did not end at the annotated position, we used TargetScan Mouse release 6.2 (Friedman *et al.* 2009; Garcia *et al.* 2011) to determine if any miRNA target sites were lost in the shorter isoforms, using information from the files Conserved site context+ scores.txt and Nonconserved site context+ scores.txt.

**Cloning.** We used nested PCR to amplify fragments of 3'UTRs from genomic mouse DNA (Promega). The PCR primers were flanked with a SacI site on the forward oligo and a NotI site on the reverse oligo. We digested the PCR products and pmirGlo (Promega) with SacI-HF and NotI-HF (NEB), then ligated them with T4 DNA Ligase (NEB). We used site-directed mutagenesis (Agilent) to mutate the miRNA target sites at two positions. Our oligo sequences are:

Eomes	Outer PCR, forward	AACTAAACTGAAGCAGACCTAGCA
Eomes	Outer PCR, reverse	TGACCAAGGAAAGAGGATTAAGCA
Eomes	Inner PCR, forward	ATATATGAGCTCATGGGAAACGAGAAATGTTTCAGAA
Eomes	Inner PCR, reverse	ATATATGCGGCCGCCGAAGTGGACAGAATATCTCCAAG
Tbx21	Outer PCR, forward	AGGTGCCCACTAACTTAGAAAACA
Tbx21	Outer PCR, reverse	ACCAGGTCCATGTTTATTTCAGA
Tbx21	Inner PCR, forward	ATATATGAGCTCGGATTCTGGGGTTTACTTCTTGT
Tbx21	Inner PCR, reverse	ATATATGCGGCCGCCAGAAAGTGATGCAAAACAGAAG
Bak1	Outer PCR, forward	CCTGGCTGGACTAAACCTCTCT
Bak1	Outer PCR, reverse	TGAAGGTGGGGTTCAAGTAATCAT
Bak1	Inner PCR, forward	ATATATGAGCTCCTGGACTAAACCTCTCTCCCTAC
Bak1	Inner PCR, reverse	ATATATGCGGCCGCATGGATGGATTGGGGTAGGAGATA
Cd69	Outer PCR, forward	CACCACAGGAAAGTTGTGTAAGT
Cd69	Outer PCR, reverse	AACAGGTTATGTGACAAGACTGGA
Cd69	Inner PCR, forward	ATATATGAGCTCGACTGCACAAACCAACTTTACATC
Cd69	Inner PCR, reverse	ATATATGCGGCCGCCCTTGAAATACGCTACAGAGGTTT
Irf1	Outer PCR, forward	CTTGACACATGGCAAAGCATAGTC
Irf1	Outer PCR, reverse	CATGACCAAACACCATTTAGCAGT
Irf1	Inner PCR, forward	ATATATGAGCTCTCTGAGTTTTCTTGAGGTTGAAG
Irf1	Inner PCR, reverse	ATATATGCGGCCGCATAGATAGTCAAGAGTCACGCCAA
Il6st	Outer PCR, forward	TAAAGACGAGTGGCTTCAGATGAG

Il6st	Outer PCR, reverse	CTGTAGGAGGACTTCTGTCATTGT
Il6st	Inner PCR, forward	ATATATGAGCTCCTTCAGATGAGAAACAGTCCTCAC
Il6st	Inner PCR, reverse	ATATATGCGGCCGCATAATAAGCAGTTTCTTGGGAGGC
Eomes upstream	Mutagenize miR-29 site, F	GCTATGAAGAACGAGTGCCCGGTACCATTAAATGAATTTCAAAG
Eomes downstream	Mutagenize miR-29 site, F	GGTATCAGATAAAAAATAATGTAAATTTGGTACCTTGGCGTTGTAAAGAATTTGC
Tbx21	Mutagenize miR-29 site, F	CAGTCACGAACCTGGTACCGCTTCTGACCCC
Tbx21	Mutagenize miR-29 site, R	GGGGTCAGAAGCGGTACCAGGTTCTGACTG
Bak1	Mutagenize miR-29 site, F	CCCCAACATTGCATGGTACCACTGAACCCCATCC
Bak1	Mutagenize miR-29 site, R	GGATGGGGTTCAGTGGTACCATGCAATGTTGGGG
Cd69	Mutagenize miR-130 site, F	CCAGTGCCTTTACGCATTAGCGCTATTTGGAGGGGTTTC
Cd69	Mutagenize miR-130 site, R	GAAACCCCTCCAAATAGCGCTAATGCGTAAAGGCACTGG
Irf1	Mutagenize miR-130 site, F	CTCTGTACTAGGAGACAATAGCGCTAAATGAGTCTATTCCC
Irf1	Mutagenize miR-130 site, R	GGGAATAGGACTCATTTAGCGCTATTGTCTCCTAGTACAGAG
Il6st	Mutagenize miR-130 site, F	GTGCTCTTTCAGAATGTTAGCGTGCCGAAAACAAAGTGTGTC
Il6st	Mutagenize miR-130 site, R	GACACACTTTGTTTTCGGCAGCGCTAACATTCTGAAAGAGCAC

**Cell culture.** HEK293 cells were used because they express negligible amounts of miR-29 and no detectable miR-130 (Mayr and Bartel 2009). They were maintained in DMEM (Gibco) supplemented with 10% FBS and penicillin/streptomycin at 37°C with 5% CO<sub>2</sub>. At 24-hours before transfection, we plated cells at 50,000 cells/mL in 24-well plates. We transfected 10 ng of the experimental plasmid and 25 nmol of miRNA mimic (IDT) using Lipofectamine 2000 (Life Technologies). We harvested the cells 24 hours later and stored them at -80°C. Luciferase amounts for Firefly and *Renilla* were measured using the Dual-Luciferase Reporter Assay system (Promega) with a dual-injection luminometer (Turner Biosystems). Firefly luciferase levels were normalized to *Renilla*. The miRNA mimic sequences are:

miR-29 sense strand	UAGCACCAUCUGAAAUCGGUUA
miR-29 anti-sense strand	ACCGAUUUCAGAUGGUGUUAAU
miR-130 sense strand	CAGUGCAAUGUAAAAGGGCAU
miR-130 anti-sense strand	GCCCUUUUAACAUUGCACAGAU

## Literature Cited

- Friedländer M. R., Mackowiak S. D., Li N., Chen W., Rajewsky N., 2012 miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. *Nucleic Acids Res.* **40**: 37–52.
- Friedman R. C., Farh K. K.-H., Burge C. B., Bartel D. P., 2009 Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **19**: 92–105.
- Garcia D. M., Baek D., Shin C., Bell G. W., Grimson A., Bartel D. P., 2011 Weak seed-pairing stability and high target-site abundance decrease the proficiency of *Isy-6* and other microRNAs. *Nat. Struct. Mol. Biol.* **18**: 1139–1146.
- Kozomara A., Griffiths-Jones S., 2014 miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res.* **42**: D68–D73.
- Langmead B., Trapnell C., Pop M., Salzberg S. L., 2009 Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**: R25.
- Langmead B., Salzberg S. L., 2012 Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**: 357–359.
- Lewis B. P., Burge C. B., Bartel D. P., 2005 Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets. *Cell* **120**: 15–20.
- Lianoglou S., Garg V., Yang J. L., Leslie C. S., Mayr C., 2013 Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. *Genes Dev.* **27**: 2380–2396.
- Mayr C., Bartel D. P., 2009 Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* **138**: 673–684.
- Quinlan A. R., Hall I. M., 2010 BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**: 841–842.
- Reynolds A. P., Richards G., Iglesia B. de la, Rayward-Smith V. J., 2006 Clustering Rules: A Comparison of Partitioning and Hierarchical Clustering Algorithms. *J. Math. Model. Algorithms* **5**: 475–504.
- Robinson M. D., McCarthy D. J., Smyth G. K., 2010 edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinforma. Oxf. Engl.* **26**: 139–140.
- Trapnell C., Pachter L., Salzberg S. L., 2009 TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**: 1105–1111.
- Trapnell C., Hendrickson D. G., Sauvageau M., Goff L., Rinn J. L., Pachter L., 2013 Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat. Biotechnol.* **31**: 46–53.